NASDAQ · PHARMACEUTICAL PREPARATIONS · SMALL CAP
Xenetic Biosciences, Inc. XBIO
14 fiscal years on record · USD · FY2025 reported · SEC filings only
$-2.7M
Growth
USD 3.0M
Revenue, FY2025 · full 14-year series below
Revenue $M
Net income $M
FY2025 · Revenue 3.0 · Net income -2.7
Compound annual growth
Revenue compounded at +46.8% a year over five years.
Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.
Profitability
−90 cents
lost on every revenue dollar
Operating margin
Net margin
FY2025 · Operating -95.2% · Net -90.1%
ROE
FY2025 · ROE -40.0%
Each USD of equity lost 40 cents this year.
The 14-year record
14 fiscal years
Every figure from documents filed with the SEC · USD
EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.
row low → row highnegative
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue $B | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Operating income $B | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 |
| EBITDA $B | · | · | · | · | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 |
| Income tax $B | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | −0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | · |
| Net income $B | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.1 | −0.0 | −0.0 | −0.0 | −0.0 |
| Free cash flow $B | · | · | · | · | · | · | · | −0.0 | 0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 |
| EPS, diluted $ | −1.58 | −2.57 | −2.71 | −4.61 | −0.55 | −1.70 | −6.33 | −9.66 | −0.41 | −7.84 | −2.96 | −0.11 | −0.07 | −0.05 |
| Dividend / sh $ | · | · | · | · | · | · | · | · | · | · | · | · | · | · |
| Payout % | · | · | · | · | · | · | · | · | · | · | · | · | · | · |
| ROE % | −40.0 | −50.1 | −35.3 | −40.9 | −36.9 | −74.0 | −94.2 | −60.3 | −23.6 | −475.9 | −146.4 | −123.9 | −51.4 | −0.4 |
| Shares out B | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.00 | 0.00 | 0.14 | 0.12 | 0.12 |
Slide the table for earlier years · "·" marks a figure not available in our data for that year.
Provenance
Company facts, as filed
How we verify · 0 failures in 59 reconciliationsAUDITED
Reconciled in 14 of 19 fiscal years. 36 checks could not be computed.
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente0 failures
ActivityPharmaceutical Preparations
Listed onNASDAQ
Incorporated inNevada
Fiscal year endsDecember 31
SEC categorysmaller reporting company
Data on record since2012